Lapatinib (INN), used in the form of lapatinib ditosylate (USAN) (trade names Tykerb and Tyverb marketed by Novartis) is an orally active drug for breast...
17 KB (1,479 words) - 09:07, 5 September 2024
Quinazoline (section Lapatinib)
drug lapatinib was approved by the U.S. FDA to treat advanced-stage or metastatic breast cancer in combination with Roche's capecitabine. Lapatinib eliminates...
14 KB (1,240 words) - 01:14, 27 July 2024
8 months (30.9 months vs. 25.1 months) compared to the combination of lapatinib and capecitabine. Based on that trial, the U.S. Food and Drug Administration...
29 KB (2,696 words) - 14:16, 27 July 2024
while attempting to determine the toxicity and effectiveness of the drug. Lapatinib, FDA-approved for treatment in conjunction with chemotherapy or hormone...
10 KB (1,179 words) - 18:31, 8 August 2024
vulnerability to oxytosis/ferroptosis via a combination of siramesine and lapatinib. These cells also exhibited an autophagic cycle independent of ferroptotic...
24 KB (2,638 words) - 00:26, 29 August 2024
this setting. Sorafenib (Nexavar) Sunitinib (Sutent) Dasatinib (Sprycel) Lapatinib (Tykerb) Nilotinib (Tasigna) Bosutinib (Bosulif) Ponatinib (Iclusig) Asciminib...
20 KB (2,234 words) - 01:21, 22 July 2024
to develop new therapeutic strategies. HER2 kinase inhibitors, such as lapatinib, have also demonstrated clinical efficacy in HER2 overexpressing breast...
18 KB (2,105 words) - 01:40, 20 August 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
68 KB (5,999 words) - 20:41, 31 August 2024
Lantidra Lantrisul Lantus (Sanofi-Aventis) lapaquistat acetate (USAN) lapatinib ditosylate (USAN) lapirium chloride (INN) laprafylline (INN) lapuleucel-T...
4 KB (281 words) - 04:55, 21 August 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
31 KB (3,430 words) - 05:24, 28 August 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
92 KB (8,688 words) - 04:50, 27 September 2024
antibody margetuximab can also prolong survival, as can HER2 inhibitors lapatinib, neratinib, or tucatinib. Certain therapies are targeted at those whose...
133 KB (14,978 words) - 19:59, 26 September 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
64 KB (7,430 words) - 15:53, 14 September 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
10 KB (1,131 words) - 19:14, 31 March 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
149 KB (15,717 words) - 14:45, 15 September 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
10 KB (579 words) - 06:46, 26 June 2024
Clinical trials are in progress for other drugs such as everolimus, lapatinib and mifepristone. Common aspirin has been studied as a low-risk therapeutic...
59 KB (6,716 words) - 04:00, 16 August 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
17 KB (1,559 words) - 21:20, 27 September 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
24 KB (1,710 words) - 19:18, 30 August 2024
1) SPOCK2 (Testican 2) SPOCK3 (Testican 3) Testican-1 plays a role in lapatinib resistance, which is a drug used to treat HER2-positive gastric cancer...
2 KB (239 words) - 07:09, 17 November 2023
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
15 KB (844 words) - 18:08, 21 March 2024
approved anti-HER2 therapeutics are also tyrosine kinase inhibitors (Lapatinib, Neratinib, and Tucatinib) and antibody-drug conjugates (ado-trastuzumab...
43 KB (4,651 words) - 13:41, 27 July 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
5 KB (412 words) - 23:17, 19 June 2023
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
13 KB (1,177 words) - 02:19, 4 September 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
11 KB (934 words) - 14:21, 19 September 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
34 KB (3,021 words) - 12:39, 5 August 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
121 KB (13,799 words) - 18:31, 13 September 2024
Uncommon (0.1-1% frequency) Keratitis Interstitial lung disease Like lapatinib and neratinib, afatinib is a protein kinase inhibitor that also irreversibly...
15 KB (1,122 words) - 15:16, 4 August 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
26 KB (2,420 words) - 02:40, 26 September 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
21 KB (1,640 words) - 06:51, 18 September 2024